Skip to main content
. Author manuscript; available in PMC: 2018 Mar 8.
Published in final edited form as: Cardiol Res Cardiovasc Med. 2017 Jan 11;2017(1):CRCM-111.

Table 2.

WHO sub categorizations of Group 1 study patients.

WHO sub-categorizations (& actual
clinical diagnoses), n(%)
Group 1 patients
(n=64)
Group 1.1 (idiopathic) 28(43.8%)
Group 1.2 (BMPR2) 2(3.1%)
Group 1.3 (Anorexigen-induced) 1(1.6%)
Group 1.4.1 (SLE, Scleroderma [including CREST], polymyositis/dermatomyositis, poly mystic with overlap syndrome, ill defined [RA vs Sjögren’s]) 23(36%)
Group 1.4.3 (portal hypertension) 5(7.8%)
Group 1.4.4 (ASD) 5(7.8%)